GlaxoSmithKline plc won the first-ever US Food and Drug Administration approval for a therapeutic targeting B-cell maturation antigen (BCMA) on 5 August and plans to make Blenrep (belantamab mafodotin) available before the end of the month. The antibody-drug conjugate (ADC) is indicated for the treatment of relapsed or refractory multiple myeloma after at least four prior rounds of treatment, including an immunomodulatory drug, proteasome inhibitor and an anti-CD38 antibody.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
More from New Products
More from Scrip
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.